Protocol Details
Age-Related Eye Disease Study (AREDS) and AREDS2 Follow-Up
This study is NOT currently recruiting participants.
Summary
Number | 08-EI-0043 |
Sponsoring Institute | National Eye Institute (NEI) |
Recruitment Detail | Type: No longer recruiting/follow-up only
Gender: Male & Female
Min Age: 50 Years
Max Age: 100 Years |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Cataract;
Age-Related Macular Degeneration;
Age-Related Macular Degeneration (AMD);
Cataracts;
Natural History |
Recruitment Keyword(s) | Age Related Macular Degeneration;
AMD;
Cataract |
Condition(s) | Age-Related Macular Degeneration;
Cataract |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Eye Institute |
This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts. Participants in the former AREDS protocol are eligible for this study.
Participants have a complete eye examination once a year and are contacted at least once a year between visits to check on their status. The eye examination includes measurement of visual acuity (vision chart test) and examination of the inside of the eye after the pupils have been dilated with eye drops. Photographs of the inside of the eye may be taken using a special camera that flashes a bright light in the eye. A blood sample may be obtained to test for cholesterol level and genes related to inflammation.
Eligibility
INCLUSION CRITERIA:
Participants will be eligible if they:
-Were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
-Can understand and provide informed consent.
EXCLUSION CRITERIA:
Participants will not be eligible if they:
-Are under the age of 50.
-Are not able to return to NIH for examination for the duration of the trial.
-Have any systemic diseases that compromise the ability to provide adequate ophthalmologic examination.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT00594672